228 related articles for article (PubMed ID: 20660574)
1. Preclinical and clinical evidence that Deoxy-2-[18F]fluoro-D-glucose positron emission tomography with computed tomography is a reliable tool for the detection of early molecular responses to erlotinib in head and neck cancer.
Vergez S; Delord JP; Thomas F; Rochaix P; Caselles O; Filleron T; Brillouet S; Canal P; Courbon F; Allal BC
Clin Cancer Res; 2010 Sep; 16(17):4434-45. PubMed ID: 20660574
[TBL] [Abstract][Full Text] [Related]
2. (18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
van Gool MH; Aukema TS; Schaake EE; Rijna H; Codrington HE; Valdés Olmos RA; Teertstra HJ; van Pel R; Burgers SA; van Tinteren H; Klomp HM
Ann Surg Oncol; 2014 Sep; 21(9):2831-7. PubMed ID: 24845729
[TBL] [Abstract][Full Text] [Related]
3. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma.
Roh JL; Yeo NK; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Oral Oncol; 2007 Oct; 43(9):887-93. PubMed ID: 17207656
[TBL] [Abstract][Full Text] [Related]
4. Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography.
Zander T; Scheffler M; Nogova L; Kobe C; Engel-Riedel W; Hellmich M; Papachristou I; Toepelt K; Draube A; Heukamp L; Buettner R; Ko YD; Ullrich RT; Smit E; Boellaard R; Lammertsma AA; Hallek M; Jacobs AH; Schlesinger A; Schulte K; Querings S; Stoelben E; Neumaier B; Thomas RK; Dietlein M; Wolf J
J Clin Oncol; 2011 May; 29(13):1701-8. PubMed ID: 21422426
[TBL] [Abstract][Full Text] [Related]
5. PET monitoring of therapy response in head and neck squamous cell carcinoma.
Schöder H; Fury M; Lee N; Kraus D
J Nucl Med; 2009 May; 50 Suppl 1():74S-88S. PubMed ID: 19380408
[TBL] [Abstract][Full Text] [Related]
6. 18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice.
McLarty K; Fasih A; Scollard DA; Done SJ; Vines DC; Green DE; Costantini DL; Reilly RM
J Nucl Med; 2009 Nov; 50(11):1848-56. PubMed ID: 19837760
[TBL] [Abstract][Full Text] [Related]
7. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
Wu ZJ; Zhang YX; Wei H; Jia Q
Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
[TBL] [Abstract][Full Text] [Related]
8. Screening for distant metastases before salvage surgery in patients with recurrent head and neck squamous cell carcinoma: a retrospective case series comparing thoraco-abdominal CT, positron emission tomography and abdominal ultrasound.
Fakhry N; Michel J; Colavolpe C; Varoquaux A; Dessi P; Giovanni A
Clin Otolaryngol; 2012 Jun; 37(3):197-206. PubMed ID: 22520870
[TBL] [Abstract][Full Text] [Related]
9. 2-[18F]-2-deoxy-D-glucose (FDG) uptake in human tumor cells is related to the expression of GLUT-1 and hexokinase II.
Ong LC; Jin Y; Song IC; Yu S; Zhang K; Chow PK
Acta Radiol; 2008 Dec; 49(10):1145-53. PubMed ID: 18979289
[TBL] [Abstract][Full Text] [Related]
10. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
[TBL] [Abstract][Full Text] [Related]
11. 111In-cetuximab-F(ab')2 SPECT and 18F-FDG PET for prediction and response monitoring of combined-modality treatment of human head and neck carcinomas in a mouse model.
van Dijk LK; Boerman OC; Franssen GM; Kaanders JH; Bussink J
J Nucl Med; 2015 Feb; 56(2):287-92. PubMed ID: 25552666
[TBL] [Abstract][Full Text] [Related]
12. (18)F-FDG-PET/CT versus panendoscopy for the detection of synchronous second primary tumors in patients with head and neck squamous cell carcinoma.
Haerle SK; Strobel K; Hany TF; Sidler D; Stoeckli SJ
Head Neck; 2010 Mar; 32(3):319-25. PubMed ID: 19626642
[TBL] [Abstract][Full Text] [Related]
13. Delayed response assessment with FDG-PET-CT following (chemo) radiotherapy for locally advanced head and neck squamous cell carcinoma.
Prestwich RJ; Subesinghe M; Gilbert A; Chowdhury FU; Sen M; Scarsbrook AF
Clin Radiol; 2012 Oct; 67(10):966-75. PubMed ID: 22595082
[TBL] [Abstract][Full Text] [Related]
14. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.
Bruzzese F; Di Gennaro E; Avallone A; Pepe S; Arra C; Caraglia M; Tagliaferri P; Budillon A
Clin Cancer Res; 2006 Jan; 12(2):617-25. PubMed ID: 16428508
[TBL] [Abstract][Full Text] [Related]
15. Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer using 3'-deoxy-3'-[18F]-fluorothymidine positron emission tomography.
Iommelli F; De Rosa V; Gargiulo S; Panico M; Monti M; Greco A; Gramanzini M; Ortosecco G; Fonti R; Brunetti A; Del Vecchio S
Clin Cancer Res; 2014 Sep; 20(18):4806-15. PubMed ID: 25052479
[TBL] [Abstract][Full Text] [Related]
16. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
17. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients.
Börjesson PK; Jauw YW; Boellaard R; de Bree R; Comans EF; Roos JC; Castelijns JA; Vosjan MJ; Kummer JA; Leemans CR; Lammertsma AA; van Dongen GA
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2133-40. PubMed ID: 16609026
[TBL] [Abstract][Full Text] [Related]
18. Current use of 18F-fluorodeoxyglucose positron emission tomography and combined positron emission tomography and computed tomography in squamous cell carcinoma of the head and neck.
Zimmer LA; Branstetter BF; Nayak JV; Johnson JT
Laryngoscope; 2005 Nov; 115(11):2029-34. PubMed ID: 16319618
[TBL] [Abstract][Full Text] [Related]
19. Lymph node metastasis of squamous cell carcinoma from an unknown primary in the upper and middle neck: Impact of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography.
Deron PB; Bonte KM; Vermeersch HF; Van de Wiele C
Cancer Biother Radiopharm; 2011 Jun; 26(3):331-4. PubMed ID: 21711095
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of 18F-FDG PET/CT and CT/MRI with histopathologic correlation in patients undergoing salvage surgery for head and neck squamous cell carcinoma.
Kim SY; Kim JS; Yi JS; Lee JH; Choi SH; Nam SY; Cho KJ; Lee SW; Kim SB; Roh JL
Ann Surg Oncol; 2011 Sep; 18(9):2579-84. PubMed ID: 21409485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
